ResMed gets US clearance for VPAP II:
This article was originally published in Clinica
ResMed has received US FDA clearance to market its bilevel continuous positive airway pressure (CPAP) system, VPAP II ST. The system, which is already on sale outside the US, has both spontaneous and timed-mode features. ResMed's Autoset portable CPAP system received FDA clearance in July. The company, which is based in Sydney, Australia, floated on the Nasdaq in June 1995 (see Clinica No 662, p 14). About 20 million Americans suffer from sleep apnoea.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.